HK-listed Alphamab Oncology hits 7-week high on Stock Connect inclusion

Alphamab Oncology

28/12/2020 04:17

** Shares of clinical-stage biopharmaceutical company
Alphamab Oncology  9966.HK  surge as much as 13.9% to HK$17.16,
highest since Nov. 11
    ** Stock last up 12.6%, on course for the best session since
May 18; among the top 30 percentage gainers on the Hong Kong
bourse 
    ** Jiangsu-based firm says it has been included in the Hong
Kong Stock Connect list under the Shenzhen-Hong Kong Stock
Connect, effective Dec. 28  urn:newsml:reuters.com:*:nFWN2J408V
    ** Co. says the inclusion in two-way trading programs
linking mainland and Hong Kong exchanges will enhance its
reputation in the capital market, broaden investor base and
increase trading liquidity 
    ** The Hong Kong Hang Seng Commerce & Industry Index  .HSNC 
falls 1.7%
    ** The Hang Seng China enterprises index  .HSCE  slips 0.7%,
while the benchmark index  .HSI  edges up 0.04%
    ** Alphamab stock up 7.6% this year, as of last close 

 (Reuters Messaging: donny.kwok.thomsonreuters.com@reuters.net)